Baird Initiates Coverage on Abbott Laboratories (ABT) with Outperform Rating

On June 30, Baird initiated coverage on Abbott Laboratories (NYSE: ABT) with an "Outperform" rating and a price target of $121.00 per share. The firm believes Abbott's portfolio will deliver steady top-line and earnings growth over the next several years.

Rating Change

Prior to this initiation, Baird had no previous rating on ABT. The new rating is "Outperform," indicating an expectation of above-average performance relative to the broader market.

Analyst Rationale

Baird analysts view Abbott Laboratories as having a strong and diversified portfolio spanning medical devices, pharmaceuticals, and nutrition, which provides stable revenue streams. The company also benefits from its leadership position in certain markets, making it one of the best monopoly stocks to buy according to hedge funds.

Context

The positive coverage comes as ABT trades near $110, offering potential upside of about 10% to the $121 target. Other analysts have mixed views, but most current ratings range between "Buy" and "Hold."

What We Conclude

Baird's optimistic initiation reflects confidence in Abbott's strategy and business model. Investors may see the $121 price target as an indication of reasonable return potential, though market and sector risks should be considered.